Combination therapy for choroidal neovascularisation

Drugs and Aging

Volumn 24, Issue 12, 2007, Pages 979-990

  Augustin, Albert J ^a   Offermann, Indre ^a  

^a Klinikum Karlsruhe   (Germany)

Author keywords

Anecortave, therapeutic use; Bevacizumab, therapeutic use; Choroidal neovascularisation, treatment; Dexamethasone, therapeutic use; Laser therapy; Pegaptanib, therapeutic use; Photochemotherapy; Ranibizumab, therapeutic use; Research and development

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

AGING; ANGIOID STREAK; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAOCULAR PRESSURE; MONOTHERAPY; MYOPIA; OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISION; VITRECTOMY;

EID: 36349031109     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724120-00002     Document Type: Review

References (88)

1. Delcourt C, Lacroux A, Carriere I, et al. The three-year incidence of age-related macular degeneration: the 'Pathologies Oculaires Liees a l'Age' (POLA) prospective study. Am J Ophthalmol 2005; 140 (5): 924-6
2. Buch H, Nielsen NV, Vinding T, et al. 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology 2005; 112 (5): 787-98
3. Bjornsson OM, Syrdalen P, Bird AC, et al. The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. Acta Ophthalmol Scand 2006; 84 (5): 636-41
4. Li Y, Xu L, Jonas JB, et al. Prevalence of age-related maculopathy in the adult population in China: the Beijing eye study. Am J Ophthalmol 2006; 142 (5): 788-93
5. Mukesh BN, Dimitrov PN, Leikin S, et al. Five-year incidence coherof age-related maculopathy: the Visual Impairment Project. Ophthalmology 2004; 111 (6): 1176-82
6. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122 (4): 564-72
7. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114 (2): 253-62
8. Varma R, Fraser-Bell S, Tan S, et al. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 2004; 111 (7): 1288-97
9. Munoz B, Klein R, Rodriguez J, et al. Prevalence of age-related macular degeneration in a population-based sample of Hispan- neovascuic people in Arizona: Proyecto VER. Arch Ophthalmol 2005; 123 (11): 1575-80
10. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006; 124 (4): 529-35
11. Schrader WF. Age-related macular degeneration: a socioeconomic time bomb in our aging society [in German]. Ophthalmologe 2006; 103 (9): 742-8
12. Glacet-Bernard A, Benyelles N, Dumas S, et al. Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 2007; 143: 68-76
13. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci 2006; 83: 316-25
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP Report 2. Arch Ophthalmol 2001; 119: 198-207
15. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131: 541-60
16. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial. VIP Report No. 3. Ophthalmology 2003; 110: 667-73
17. Kaiser PK, on behalf of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006; 244 (9): 1132-42
18. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
19. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-4
20. Genentech. Lucentis® (ranibizumab injection) prescribing information. San Francisco (CA): Genentech, 2006 [online]. Available from URL: http://www.gene.com/gene/products/information/tgr/lucentis/index.jsp [Accessed 2006 Feb 23]
21. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143 (4): 566-83
22. Genentech. Avastin® (bevacizumab) prescribing information. San Francisco (CA): Genentech, 2006 [online]. Available from URL: http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp [Accessed 2006 Feb 23]
23. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (3): 363-72
24. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascuic larization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245 (1): 68-73
25. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006; 47 (10): 4569-78
26. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91 (2): 157-60
27. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142 (1): 1-9
28. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26 (4): 383-90
29. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351 (27): 2805-16
30. Chakravarthy U, Adamis AP, Cunningham Jr ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (9): 1508.e1-25
31. Slakter JS, Bochow T, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006; 113 (1): 3-13
32. Russell SR, Hudson HL, Jerdan JA, et al. Anecortave acetate for the treatment of exudative age-related macular degeneration: a review of clinical outcomes. Surv Ophthalmol 2007; 52 Suppl. 1: 79-90
33. Challa J, Gillies M, Penfold P, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998; 26 (4): 277-81
34. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20 (3): 244-50
35. Jonas JB, Degenring RF, Kreissig I, et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomised study. Eye 2004; 19 (2): 163-70
36. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122 (3): 336-40
37. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006; 90 (9): 1188-96
38. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31
39. Chauvaud D. The place of surgery in subfoveal neovascular treatment in age-related macular degeneration [in French]. J Fr Ophtalmol 2002; 25 (7): 756-9
40. Gelisken F, Voelker M, Schwabe R, et al. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007; 245 (8): 1085-95
41. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999; 237 (4): 313-25
42. Marcus DM, Peskin E, Maguire M. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004; 138 (5): 818-28
43. Feucht M, Fuisting B, Richard G. Status of TTT in the therapy for CNV [in German]. Klin Monatsbl Augenheilkd 2006; 223 (10): 802-7
44. Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 2007; 23 (3): 477-87
45. Augustin AJ, Offermann I. Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs 2006; 11 (4): 725-40
46. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27 (2): 133-40
47. Shastry BS. Assessment of the contribution of the LOC387715 gene polymorphism in a family with exudative age-related macular degeneration and heterozygous CFH variant (Y402H). J Hum Genet 2007; 52 (4): 384-7
48. Moshfeghi DM, Blumendranz MS. Role of genetic factors and inflammation in age-related macular degeneration. Retina 2007; 27: 269-75
49. Narayanan R, Butani V, Boyer DS, et al. Complement factor H polymorphism in age-related macular degeneration. Ophthalmology 2007; 114 (7): 1327-31
50. Shuler Jr RK, Hauser MA, Caldwell J, et al. Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism. Arch Ophthalmol 2007; 125 (1): 63-7
51. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006; 141: 149-56
52. Schmidt-Eurfurth U, Scholtzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44 (10): 4473-80
53. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-8
54. Tatar O, Shinoda K, Adam A, et al. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Br J Ophthalmol 2007; 91: 166-73
55. Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 2007; 104 (3): 967-72
56. Kaiser PK. Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opin 2005; 21 (5): 705-13
57. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration. Eur J Ophthalmol 2006; 16 (6): 824-34
58. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006; 90 (3): 337-41
59. Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic agetherapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006; 113 (12): 2243-50
60. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113 (1): 14-22
61. Spaide R, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110 (8): 1517-25
62. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88 (3): 344-7
63. Van De Moere A, Sandhu SS, Kak R, et al. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005; 112 (11): 1896-903
64. Nicolo M, Ghiglione D, Lai S, et al. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006; 26 (1): 58-64
65. Augustin AJ, Schmidt-Erfuth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-45
66. Ruiz-Moreno JA, Montero JA, Barile S, et al. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006; 26: 602-12
67. Fackler TK, Reddy S, Bearelly S, et al. Retrospective review of eyes with neovascular age-related macular degeneration treated with photodynamic therapy with verteporfin and intravitreal triamcinolone. Ann Acad Med Singapore 2006; 35 (10): 701-5
68. Marticorena J, Gomez-Ulla F, Fernandez M, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006; 142 (2): 335-7
69. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 174-9
70. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-85
71. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110 (5): 979-86
72. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124: 1532-42
73. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26 (9): 988-93
74. Schmidt-Erfurth U, Gabel P, Hohman T, et al. Preliminary results from an open-label, multicenter, phase II study assessing the effects of same-day administration of ranibizumab (Lucentis™) and verteporfin PDT (PROTECT Study) [abstract no. 2960]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
75. Funk M, Michels S, Wagner J, et al. Vascular effects of combined ranibizumab (Lucentis®) and verteporfin (Visudyne®) therapy in patients with neovascular age-related macular degeneration [abstract no. 353]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
76. Wagner J, Simader C, Kiss C, et al. Changes in functional macular mapping in patients with neovascular age-related macular degeneration receiving combination of verteporfin (Visudyne™) and ranibizumab (Lucentis®) therapy [abstract no. 363]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
77. Wolf S, Gabel P, Hohman TC, et al. Fluorescein angiographic and OCT results from an open-label, multicenter, phase II study assessing the effects of same-day ranibizumab (Lucentis™) and verteporfin PDT (Visudyne®) [abstract no. 3542]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
78. Eter N, Ladewig M, Hamelmann V, et al. Combined intravitreal bevacizumab (Avastin) and photodynamic therapy for AMD [abstract no. PO341]. Annual meeting of the American Academy of Ophthalmology (AAO); Las Vegas (NV); 2006 Nov 12 [online]. Available from URL: http://www.aao.org/annual_meeting/program/ onlineprogram06.cfm [Accessed 2007 Mar 15]
79. Colina-Luquez Jm, Liggett Pe, Tom D, et al. Prospective and preliminary study evaluating triple therapy of intravitreal triamcinolone, photodynamic therapy and pegaptanib sodium for choroidal neovascularization [abstract no. 349]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
80. Offermann I, Altinay A, Schmidt-Erfurth U, et al. Intravitreal bevacizumab for the treatment of remaining choroidal neovascularization (CNV) activity following combination therapy (PDT and triamcinolone) [abstract no. 2154]. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Fort Lauderdale (FL)
81. Bay Area Retinal Associates, QLT Inc. Triple therapy: PDT plus IVD and intravitreal ranibizumab versus monotherapy: intravitreal ranibizumab alone for the treatment of age-related macular degeneration [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00390208?.order = 1 [Accessed 2007 May 31]
82. Vitreous-Retina-Macula Consultants of New York, QLT Inc. Second line therapy to treat AMD for patients not responding well to Lucentis therapy by itself [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/ NCT00457678?.order = 2 [Accessed 2007 May 31]
83. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125 (3): 309-17
84. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19 (3): 361-72
85. Mares JA, La Rowe TL, Blodi BA. Doctor, what vitamins comshould I take for my eyes? Arch Ophthalmol 2004; 122: 628-35
86. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36
87. Desmettre T, Lecerf JM, Souied EH. Nutrition and age-related macular degeneration [in French]. J Fr Ophtalmol 2004; 27 (9 Pt 2): 3S38-56
88. Moeller SM, Parekh N, Tinker L, et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the carotenoids in age-related eye disease study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol 2006; 124 (8): 1151-62